Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 vs mFOLFOX6 + Aflibercept in Rectal Cancer
NCT03043729Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Mar 2017
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in rectal cancer (2 arms), sponsored by AIO-Studien. Primary endpoint: Pathologic Complete Response at 20 weeks. Started Mar 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03043729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043729.